Breadcrumb links

Navigation

Cambridge teams awarded grant for biosensor research

21 November 2005

Researchers from the University of Cambridge and the Medical Research Council (MRC) are part of a consortium which has been awarded a nearly £1M grant from the Biotechnology and Biological Sciences Research Council (BBSRC). The research project focuses on the development of new “biosensors” for the detection of markers of cancer and infectious diseases.

The Cambridge branch of the project is being led by Dr Paul Ko Ferrigno from the MRC Cancer Cell Unit and Professor Piero Migliorato from the University of Cambridge’s Department of Engineering.  Other groups funded by the BBSRC include Dr Jason Davis from the Oxford University Chemistry Department (Project Leader), and Dr Ejaz Huq from the Central Microstructure Facility at the Rutherford Appleton Laboratory.  These groups will provide the project with essential expertise in surface chemistry, electroanalysis, imaging and microfabrication.

The goal of the project is to produce low cost disposable sensors that can have applications such as identifying cancer markers in patient samples. These portable sensors would have the capability to process 100,000 signals simultaneously and would be suitable for home or field use as well as for specialised laboratories.

Professor Migliorato’s group has shown that electrical signals can be generated and detected after strands of DNA interact and pair with each other. These signals can be detected by specially designed polycrystalline silicon thin film transistors (TFTs). These electronic devices, which are ten times smaller than a grain of salt, are similar to those employed to produce images in LCD computer and TV screens.  

Dr Ko Ferrigno’s group has developed “peptide aptamers”, which are special types of proteins that can be coupled to the TFTs to detect the presence of other proteins in a sample. This technology has many applications including the potential to be used to detect markers of avian flu virus infection in patient samples. These peptide aptamers provide a substantial advance over other current technologies.

Professor Migliorato said: “Polycrystalline silicon TFTs are used to fabricate microcircuits on glass or plastics, the main present application being in multi-functional mobile phones. The biosensor system we have in mind is similar to a mobile phone: a compact, low power consumption portable instrument, with a video and wireless interface, which can be used at the patient bed as well as in the field. The range of applications is enormous, from medical to forensic, environment protection and bioterrorism prevention.”

Dr Ko Ferrigno said: “Such a device would solve not one but two different problems. The first is that it would enable population-wide screening, at home or in a doctor's surgery, to allow early diagnosis of diseases such as cancer- where the earlier we pick up symptoms, the more effectively we can treat the patient. The second is that biologists will finally have a tool that will allow them to answer literally hundreds of thousands of questions simultaneously- all for the price of a new test tube! This is an unusual marriage of biology and cutting edge engineering that should really pay dividends in our own lifetimes.”

Notes for editors:

  • 1. The Department of Engineering is the largest department in the University of Cambridge, representing approximately 10% of the University's activities by the majority of common metrics, and is one of Europe's largest integrated engineering departments. It achieves the highest standards in both research and teaching. Its international reputation attracts the best students, academics, sponsors and partners from around the world.
  • 2. The Medical Research Council (MRC) is a national organisation funded by the UK tax-payer. Its business is medical research aimed at improving human health; everyone stands to benefit from the outputs. The research it supports and the scientists it trains meet the needs of the health services, the pharmaceutical and other health-related industries and the academic world. MRC has funded work which has led to some of the most significant discoveries and achievements in medicine in the UK. About half of the MRC's expenditure of approximately £500 million is invested in its 40 Institutes, Units and Centres. The remaining half goes in the form of grant support and training awards to individuals and teams in universities and medical schools.
  • For more information contact:
  • 1. Karen Dean, Press and Publications Office, University of Cambridge. Tel: 01223 765542; email: kjd42@cam.ac.uk
  • 2. Adrian Penrose, Medical Research Council (MRC) Tel:  01223 748179; email:  ap454@medschl.cam.ac.uk
  • 3. Professor Piero Migliorato, Department of Engineering, University of Cambridge. Email: pm@eng.cam.ac.uk
  • 4. Dr Paul Ko Ferrigno, Group Leader, MRC Cancer Cell Unit. Email: pkf24@cam.ac.uk
    MRC YouTube channel

                
    Contact Us
    • Comment?
    • Question?
    • Request?
    • Complaint?

    Get in touch

    This page as PDF